Moderna Announces IND Submitted to U.S. FDA for Phase 2 Study of mRNA Vaccine (mRNA-1273) Against Novel Coronavirus - Business Wire

Moderna Announces IND Submitted to U.S. FDA for Phase 2 Study of mRNA Vaccine (mRNA-1273) Against Novel Coronavirus  Business Wire

Comments

Popular posts from this blog

8 Ways to Get Care When There Are No Primary Care Doctors - U.S. News & World Report

Vaccines Offer Protection Against Cold and Cough Symptoms - Pharmacy Times